ArticleThe Journal of nutrition2025
Protective Role of Dietary Short-Chain Fatty Acid Propionate against Autoimmune Responses and Pathology of Systemic Lupus Erythematosus in MRL-lpr Mice.
Article in The Journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Establishment of a novel lupus mesenteric vasculitis mouse model and exploration of its exacerbation mechanisms.Frontiers in immunology · 2026Article
- Breaking the cycle: immune complexes, complement activation, and novel immunotherapies in lupus nephritis.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSystemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs, including the skin and kidneys. The etiology of SLE remains unclear but involves hormonal, environmental, and genetic factors. Environmental factors, such as diet and microbiota-derived metabolites, among which short-chain fatty acids (SCFAs) are major players, can influence autoimmune disease pathogenesis.
objectivesThis study investigates the involvement of SCFAs in the pathogenesis of SLE and further investigates the effect of propionate (PA) supplementation on SLE disease outcome in MRL-lpr mice.
methodsCecal SCFAs from mouse models with varying degrees of SLE disease activities (C57BL/6, MRL+/+, and MRL-lpr) were determined by liquid chromatography/MS analysis. Five-week-old MRL-lpr mice were supplemented with PA (200 mM, via drinking water) for 6 wk, and assessed for autoimmunity and disease markers.
resultsLiquid chromatography/mass analysis of cecal SCFAs showed a significant decrease of PA in MRL-lpr mice (P < 0.001). PA treatment ameliorated the autoimmune response, evident from reduced serum autoantibodies (P < 0.05 for both antinuclear antibodies and anti-double-stranded deoxyribonucleic acid) and a significant alleviation of glomerulonephritis (P < 0.05). Furthermore, it restored the imbalances in gut microbiome composition and SCFAs, especially PA (P < 0.01). Additionally, PA treatment resulted in decreased splenic activated CD4 T cells (P < 0.05) and alterations in renal inflammatory signaling pathways.
conclusionsOur findings support the beneficial effects of PA in alleviating SLE and the therapeutic potential of PA or PA-producing bacteria for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.